DI-048: MANAGEMENT OF CYCLOPHOSPHAMIDE-INDUCED SYNDROME OF INAPPROPIATE ANTIDIURETIC HORMONE SECRETION IN A PATIENT WITH LIMPHOCYTIC B LIMPHOMA

I. Viguera-Guerra¹, M.C. Garzás¹, F. Franco-García¹.

¹Hospital Universitario Reina Sofía, Pharmacy Department, Córdoba, Spain.

Background

Cyclophosphamide is an alkilating agent largely used in hematology. Among its adverse events we found infections, inmunosuppression, hipersensivity reactions, hemorrhagic cystitis and neurologic toxicity. It has also been rarely described the appearance of syndrome of inappropriate antidiuretic hormone secretion (SIADH).

Purpose

To report a case of SIADH induced by ciclophosphamide in an elder patient with limphocytic B limphoma.

Materials and Methods

87 year-old man was diagnosed of limphocytic B limphoma in June 2013.

TREATMENT

Day 1: Fist-line: Chlorambucil 0.1 mg/kg/day

-> Progression on day 9

Day 10:Second-line: COP (cyclophosphamide 750mg/m² and vincristine 1 mg -> Severe neutropenia (640 cells/mm³)

Day 23: the patient was hospitalised:

- pneumonia,

- severe hyponatremia,

- decompensated cardiac insufficiency,

- hypoxemia.




SUSPECTION OF SIADH INDUCED BY CYCLOPHOSPHAMIDE

Results

LABORATORY

Day 23: [Na+p] = 119 mEq/L, [Na+u]=113 mEq/L, OsmopP=282 mOsm/Kg.



TREATMENT

Day 55: Third-line: Off-label treatment with bendamustine 90 mg/m2 day 1 and 2, receiving 3CYCLES.

Fludarabine was not considered because of history of neutropenia and pneumonia.

COMPUTERISED TOMOGRAPHY

Day 139: adenopaties had disappeared.

The ALGORITHM OF KARL-LASAGNA indicated a *probable* association between SIADH and cyclophosphamide administration.

The case was reported to the ANDALUSIAN PHARMACOVIGILANCE CENTER and registered with the number *OL-2819*.

Conclusions

It is highly important to closely monitor plasma sodium levels during treatment with cyclophosphamide for the possible occurrence of SIADH. Bendamustine treatment in monotherapy provided a safe and effective alternative in this patient.

